On June 3, 2024, Julie Hambleton, Director at SpringWorks Therapeutics Inc (NASDAQ:SWTX), sold 4,648 shares of the company.
Badreddin Edris, the Chief Operating Officer of SpringWorks Therapeutics Inc (NASDAQ:SWTX), sold 20,000 shares of the company on June 3, 2024, according to a recent SEC filing.
On June 3, 2024, Saqib Islam, the Chief Executive Officer of SpringWorks Therapeutics Inc (NASDAQ:SWTX), executed a sale of 49,000 shares of the company.